maprotiline + trazodone

Maprotiline + trazodone is a combination of two antidepressant medications, each with distinct mechanisms of action. Maprotiline is a tetracyclic antidepressant (TeCA) that primarily inhibits the reuptake of norepinephrine, with some anticholinergic activity and minimal effect on serotonin reuptake. It is used to treat depressive disorders and anxiety associated with depression[1][4]. Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI). Its mechanism involves inhibiting the reuptake of serotonin and antagonizing various serotonin receptor subtypes (notably 5-HT2A/2C), as well as blocking histamine H1 and alpha-1 adrenergic receptors[3][5]. The combination may be considered in treatment-resistant depression or when targeting both noradrenergic and serotonergic pathways, but it carries an increased risk for additive central nervous system depression, excessive sedation, QTc prolongation, orthostatic hypotension, anticholinergic effects, and potentially serotonin syndrome[1][2][4][5].